STOCKS TELEGRAPH

Tag: AKAN Stock

  • Akanda Corp. (AKAN) Regains Premarket Momentum Amidst Market Volatility

    In the ever-fluctuating stock market, Akanda Corp. (NASDAQ: AKAN) faced a challenging day yesterday, experiencing a significant dip of approximately 7.6% in its stock value. However, the company has swiftly turned the tide, with premarket trading today revealing a remarkable surge of 32%. This sudden turnaround follows a noteworthy announcement regarding the sale of its assets in Portugal to Somai Pharmaceuticals.

    Company Profile

    Akanda Corp. stands as an up-and-coming player in the cannabis space. Hailing from Britain, the company has earned a reputation for its unwavering commitment to delivering top-tier, ethically sourced medical cannabis products to patients worldwide.

    With operational facilities in Africa, Akanda specializes in supplying superior cannabis biomass, flower, and concentrates to wholesalers, while also engaging in the import and sale of medical cannabis-based products.

    Details of the Sale Agreement

    The recent revelation centers around the signing of a definitive Share Purchase Agreement and Escrow Agreement with Somai Pharmaceuticals Unipessoal, LDA for the divestiture of its Portuguese subsidiary, RPK BioPharma Unipessoal, LDA.

    As per the terms of the Share Purchase Agreement, Somai is set to acquire RPK for a total consideration of $2 million, with an initial deposit of $500,000, secured in escrow. The remaining balance will be disbursed upon the fulfillment of specified closing conditions.

    Strategic Implications and Forward Trajectory

    This pivotal transaction signifies a significant stride for both Akanda Corp. and Somai Pharmaceuticals, underscoring their joint commitment to propelling advancements within the medical cannabis industry and broadening patient access to quality treatment options.

    With the infusion of capital from the sale, Akanda is primed to bolster its financial standing and expand its foothold in the global cannabis market. Notably, the company’s UK subsidiary, Canmart, is poised to spearhead this expansion by diversifying its offerings to include third-party products and forging partnerships with clinical cannabis enterprises.

    Furthermore, Akanda’s ongoing endeavors such as the Gabriola Green Project in Canada exemplify its dedication to extending its reach across Europe and North America.

    Conclusion

    The divestiture of its Portuguese assets heralds a significant milestone for Akanda Corp., positioning the company for sustained growth and success within the competitive landscape of the medical cannabis sector.

    Armed with a fortified financial position and a strategic vision for expansion, Akanda is poised to deliver enduring value to its stakeholders and pioneer innovative solutions for patients worldwide.

  • Akanda Corp. (AKAN) Stock Enters the European Shores

    Akanda Corp. (NASDAQ: AKAN) has been seeing a remarkable price rally in recent days, which saw it climb up from $0.17 to almost $0.60, in a matter of days. Even though AKAN stock eventually fell back “down” to $0.30, its price rise remains phenomenal, and the company finds itself in the market spotlight.

    Akanda Corp. Makes Entry into the German Market

    A core reason behind why the stock of Akanda Corp. (AKAN) has been on a roll lately most likely links to the company’s recent strategic shift of targeting a 10% market share in the German cannabis market. Furthermore, the first shipment and sale to the German-licensed dispensary have recently been made, finalizing Akanda’s entry into the lucrative European market. This signifies a strategic shift for the company, as it looks to shut down its operations throughout each of its African locations and focus instead on Europe.

    AKAN sets its sights on the future

    AKAN stock may see a surge in its future growth potential, given the company’s ambitions that management has been vocal about. In fact, throughout 2022, the company has been restructuring its organization with its future trajectory in mind and has been making some serious additions to its board of directors. It further went on to hire top executives who have had exposure in Europe’s medical cannabis markets, as well as those working closely alongside EU’s GMP-licensed cultivation facilities. Therefore, these moves demonstrate a significant milestone achievement by the company, moving forward, and vastly improving its capability to execute on the European markets.

    Conclusion

    AKAN stock has been seeing a drastic surge, as it shifts gears, and focuses solely on its European expansion ambitions. Its recent entry into the German market emphasizes the degree to which it is on course to meeting this goal, and taking its business to a whole new level.